Overview Technical Risk & rank Quality Results Accounts Filings Guidance & governance
Guidance tracker
What EMCURE guided, and what came next
| Filed | What the filing says | Next results: profit YoY | Revenue | Move on the day |
|---|---|---|---|---|
| 06 Nov 2026 | Emcure filed the transcript of its Q2 FY27 earnings call held on November 3, 2026. Management reported Q2 revenue of INR2,820 crores (up 24% year-on-year), EBITDA of INR575 crores (up 31%, margin 20.4%) and profit after tax of INR325 crores (up 29%). Management raised its FY27 revenue growth outlook to exceed 20%,... NSE copy | No results filed since | ||
| 12 Aug 2026 | Emcure Pharmaceuticals filed the transcript of its Q1 FY27 earnings call held on August 6, 2026. Management said revenue grew 22.8% year-on-year to INR 2,580 crore, EBITDA rose 25.8% to INR 508 crore with margin at 19.7%, and profit after tax grew 36.2% to INR 292 crore. India revenue grew 10.2% to INR 1,095 crore;... NSE copy | +33.7 % | +24.3 % | +9.3 % |
| 12 Jun 2026 | Emcure Pharmaceuticals filed its Investor Presentation – June 2026 under Regulation 30 of the SEBI Listing Regulations, also available on the company website. FY26 revenue from operations was INR 9,204 Cr, up 16.6% YoY; EBITDA was INR 1,789 Cr at a 19.4% margin (up 80 bps); Adj. PAT was INR 1,008 Cr at a 10.9%... NSE copy | +42.1 % | +22.8 % | -1.1 % |
| 11 May 2026 | Emcure Pharmaceuticals filed the transcript of its Q4 FY26 earnings call held on May 5, 2026. Management said FY26 revenue crossed INR9,204 crores, up 16.6% year-on-year, and adjusted PAT grew more than 40%; FY26 domestic revenue grew 10% to INR4,027 crores and international revenue grew 22.2% to INR5,177 crores.... NSE copy | +42.1 % | +22.8 % | -1.1 % |
| 10 Feb 2026 | Emcure filed the transcript of its Q3 FY26 earnings call held on February 4, 2026. Management said revenue from operations grew 20.4% year-on-year to INR 2,363 crores, and profit after tax was INR 231 crores (48% growth), after a one-time exceptional expense of INR 38 crores related to Labour Code changes; adjusted... NSE copy | +28.8 % | +16.7 % | -1.8 % |
| 19 Nov 2025 | Emcure Pharmaceuticals filed an investor presentation (November 2025) for investor conferences on November 19 and 20, 2025, under Regulation 30 of the SEBI LODR Regulations. FY25 revenue from operations was INR 7,896 Cr, with 46.3% from India (FY24: INR 6,658 Cr overall); 1H FY26 revenue grew 15% to INR 4,370 Cr... NSE copy | +50.0 % | +20.4 % | +1.9 % |
| 17 Nov 2025 | Emcure filed the transcript of its Q2 FY26 earnings conference call held on November 11, 2025. Management (Satish Mehta) said revenue grew 13% YoY and PAT rose 25% to INR 251 crores, the highest quarterly profit, and the company remains on track for its high-level guidance. CFO Tajuddin Shaikh said revenue from... NSE copy | +50.0 % | +20.4 % | +1.9 % |
| 13 Aug 2025 | Emcure Pharmaceuticals filed the transcript of its Q1 FY26 earnings conference call, held on August 7, 2025. Management said revenue from operations grew 15.7% year-on-year to INR 2,101 crores, EBITDA (excluding other income) grew 20.1% to INR 404 crores, and profit after tax rose 41% to INR 215 crores, the... NSE copy | +25.1 % | +13.4 % | -2.4 % |
| 28 May 2025 | Emcure filed the transcript of its Q4 FY25 earnings call held on May 22, 2025. Management said Q4 FY25 revenue from operations grew 19.5% year-over-year to INR 2,116 crores, and FY25 revenue grew 19% to INR 7,896 crores; FY25 PAT was INR 707 crores, up 34.1%. Management guided to FY26 top-line growth of 13% to 14%... NSE copy | +43.6 % | +15.7 % | -1.5 % |
| 11 Feb 2025 | Emcure Pharmaceuticals filed the transcript of its Q3 FY25 earnings conference call held on February 6, 2025. Management said Q3 revenue from operations grew 18% year-on-year to INR 1,963 crores and adjusted PAT grew 36% year-on-year; reported PAT was INR 156 crores. CFO Tajuddin Shaikh said domestic business grew... NSE copy | - | - | +10.0 % |
Filings tagged as guidance, newest first (10 in all), with the company's next results after each: profit and revenue against the same quarter a year before, and the share's move on the results day. Whether the guidance was met is for the reader to judge from both; the site does not score it. The summaries are written by an AI model from the filing and can be wrong - the filing is the source.
Governance
Management, auditors, ratings and legal matters
| Filed | Kind | What the filing says |
|---|---|---|
| 01 Sep 2026 | Credit rating | Emcure Pharmaceuticals filed under Regulation 30 to intimate that CARE Ratings has reaffirmed its bank facility ratings (press release dated August 31, 2026, received September 1, 2026). Long-term bank facilities of Rs. 785.00 crore (enhanced from Rs. 557.50 crore) reaffirmed at CARE AA; Stable.... NSE copy |
| 12 Aug 2026 | Management change | Emcure Pharmaceuticals filed the transcript of its Q1 FY27 earnings call held on August 6, 2026. Management said revenue grew 22.8% year-on-year to INR 2,580 crore, EBITDA rose 25.8% to INR 508 crore with margin at 19.7%, and profit after tax grew 36.2% to INR 292 crore. India revenue grew 10.2% to INR 1,095 crore;... NSE copy |
| 06 Aug 2026 | Management change | Emcure Pharmaceuticals filed its investor presentation on unaudited financial results for the quarter ended June 30, 2026 (Q1 FY27). Q1 FY27 revenue was INR 25,804 Mn, up 22.8% YoY; EBITDA was INR 5,080 Mn at a 19.7% margin (up 50 bps); PAT was INR 2,925 Mn at an 11.3% margin (up 110 bps). International business... NSE copy |
| 06 Aug 2026 | Management change | Emcure Pharmaceuticals filed the outcome of its board meeting held on August 06, 2026, including unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, with limited review reports from BSR & Co. LLP and a press release on the results (figures are in the annexures, not in the... NSE copy |
| 05 May 2026 | Management change | Emcure Pharmaceuticals filed the outcome of its board meeting held on May 05, 2026, approving audited standalone and consolidated financial results for the quarter and year ended March 31, 2026, with unmodified audit opinions from statutory auditors BSR & Co. LLP. The board recommended a final dividend of Rs. 3.60... NSE copy |
| 09 Mar 2026 | Legal or regulatory, Management change | Emcure Pharmaceuticals filed the outcome of its board meeting held on March 09, 2026 (meeting ran 12:15 p.m. to 12:40 p.m. IST). The board approved the appointment of Mr. C S Muralidharan (DIN: 00014740) as Additional Director (Non-Executive and Independent) and as Independent Director for a first term of three... NSE copy |
| 04 Feb 2026 | Legal or regulatory, Management change | Board meeting held on February 04, 2026 approved unaudited consolidated and standalone financial results for the quarter and nine months ended December 31, 2025, with limited review reports from BSR & Co. LLP. Board approved appointment of Ms. Amruta Jana Yangalwar as Company Secretary and Compliance Officer. Board... NSE copy |
| 17 Oct 2025 | Credit rating | Emcure Pharmaceuticals Limited filed an intimation under Regulation 30 of the SEBI LODR Regulations on a revision in credit rating dated October 17, 2025. CRISIL Ratings Limited upgraded the long-term rating on bank loan facilities of Rs. 1957.5 crores to CRISIL AA-/Positive from CRISIL AA-/Stable. CRISIL... NSE copy |
| 08 Oct 2025 | Credit rating | Emcure Pharmaceuticals filed an intimation under Regulation 30 of the SEBI LODR Regulations on credit ratings assigned by CARE Ratings, received October 08, 2025. Long-term bank facilities of Rs. 557.50 crore upgraded to CARE AA; Stable from CARE AA-; Stable. Long-term/short-term bank facilities of Rs. 175.00 crore... NSE copy |
| 13 Aug 2025 | Management change | Emcure Pharmaceuticals filed the transcript of its Q1 FY26 earnings conference call, held on August 7, 2025. Management said revenue from operations grew 15.7% year-on-year to INR 2,101 crores, EBITDA (excluding other income) grew 20.1% to INR 404 crores, and profit after tax rose 41% to INR 215 crores, the... NSE copy |
| 21 Jun 2025 | Legal or regulatory | Emcure Pharmaceuticals filed the outcome of its board meeting held on June 21, 2025. The board approved acquisition of 4,095,180 equity shares (20.42%) of subsidiary Zuventus Healthcare Limited from its individual shareholders, making Zuventus a wholly-owned subsidiary; the company already holds 79.58%. Zuventus... NSE copy |
| 17 Jun 2025 | Legal or regulatory | Emcure Pharmaceuticals filed a Regulation 30 disclosure dated June 17, 2025 updating its May 22, 2025 intimation on a wholly-owned subsidiary. The company applied to the ROC, Pune, for the name "Emcure Lifesciences Private Limited" instead of "Emcure Generics Private Limited", and the name was approved. The ROC... NSE copy |
| 22 May 2025 | Management change | Board of Emcure Pharmaceuticals approved audited standalone and consolidated financial results for the quarter and year ended March 31, 2025, with unmodified audit opinions from statutory auditors BSR & Co. LLP. Board recommended a final dividend of Rs. 3 per equity share (30% on Rs. 10 face value) for FY2025,... NSE copy |
Filings with a management change, a legal or regulatory matter or a credit rating (by their tags), or naming an auditor, a resignation or a pledge of shares; newest first (13 in all). A list of what was filed, not a judgement of the company.